Alcon Inc. (ALC) Balance Sheet

The asset base increased by roughly 5% since 2024Q1, driven primarily by growth in goodwill and PPE, which rose from $4.7B to $5.3B. This suggests continued investment in both acquisitions and fixed assets, aligning with the company's focus on expanding its surgical and vision care capabilities. The stable debt/equity ratio implies that this growth is being funded through retained earnings or equity issuance rather than incremental borrowing, which may indicate a conservative capital structure.

The debt/equity ratio of 0.25 appears low relative to peers like Baxter (1.64) and Henry Schein (0.77), suggesting a conservative leverage profile. However, the reported total debt of $5.3B may not capture all long-term obligations, as the 2019 spin-off from Novartis involved significant debt allocation. Investors should monitor the full debt schedule to assess refinancing risk, especially given the current interest rate environment. The stable debt level over the past year suggests no aggressive borrowing, but the discrepancy warrants further investigation.

The rise in goodwill, up $400M since 2024Q1, likely stems from acquisitions such as Aerie Pharmaceuticals, which may carry impairment risk if expected synergies fail to materialize. PPE growth to $5.3B suggests ongoing capital expenditure in manufacturing and surgical equipment, consistent with the company's high fixed-cost structure. The asset mix remains asset-light relative to industrial peers, but the significant goodwill balance means that any impairment could directly impact equity, which is a key risk to monitor.

The absence of retained earnings in the data is unusual and may indicate that the company has distributed all earnings via dividends or that the figure is not separately disclosed. The equity increase of $800M aligns with net income accumulation, but the zero retained earnings line suggests a potential data limitation. Given the prior cash flow analysis showing aggressive capital returns, including $463M in dividends and buybacks in 2026Q2, equity quality appears supported by strong cash generation, though the lack of retained earnings detail limits deeper analysis.

The current ratio, though still above 2, has deteriorated by nearly 25% over the period, suggesting that current liabilities are growing faster than current assets. Cash levels have remained relatively stable around $1.4-1.6B, but the decline in the current ratio may reflect increased short-term debt or payables. Given the company's moderate capital intensity and stable operating cash flow, the liquidity buffer appears sufficient for near-term obligations, but the trend warrants monitoring if the ratio continues to decline.